Damora Therapeutics, Inc. GLTO
Set alert
21.58 USD 0.00 0.00%
As of Jun 4, 12:02 PM ET
21.58 Day range 23.54
4.40 52-week range 23.50
- YTD
- -6.21%
- 1 year
- +659.86%
- Open
- 22.26
- Prev close
- 21.58
- Mkt cap
- 6.22M
- Vol
- 609
- Avg vol
- 26.14K
- EPS
- -19.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.58
- High
- 23.54
- Forward P/E
- -0.25
- Beta
- 1.25
- Short ratio
- 1.08
- Inst. own
- 12.03%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.25
- 200-d avg
- 12.56
- 1y target
- 10.00
Key statistics
- Market cap
- 6.22M
- Enterprise value
- -13.46M
- Trailing P/E
- 0.00
- Forward P/E
- -0.25
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.28
- EPS (TTM)
- -19.11
- Beta
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.52M
- Total cash
- 19.68M
- Total debt
- 32.00K
- Return on equity
- -72.61%
- Shares outstanding
- 1.32M
- Short % of float
- 1.59%
- 50-day average
- 6.25
- 200-day average
- 12.56
Analyst view
Consensus: none
Price target (mean) 10.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.82.
Financials — quick view
GLTO Revenue — quarterly 0
GLTO Net income — quarterly -3.13M
GLTO EPS — quarterly -2.36
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2024 | Oppenheimer | main | Outperform | Outperform |
| Jun 10, 2024 | Oppenheimer | main | Outperform | Outperform |
| Sep 28, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 21, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 15, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Aug 1, 2023 | Oppenheimer | reit | Outperform | Outperform |
About Damora Therapeutics, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- galecto.com
News
- What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
- Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
- Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Galecto Announces Pricing of $275 Million Underwritten Public Offering
- Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
- Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
- Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
Your note
Sign in to keep a note on GLTO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHRISTGAU STEPHAN | Director | Purchase | Nov 1, 2020 | 0 |
| FREVE JONATHAN | Chief Financial Officer | Purchase | Dec 2, 2021 | 12,000 |
| KHUONG CHAU QUANG | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2020 | 0 |
| LINDMARK BERTIL | Officer | Purchase | Mar 21, 2022 | 16,604 |
| MUNSHI AMIT D | Director | Conversion of Exercise of derivative security | Nov 1, 2020 | 4,793 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2020 | 2,497,790 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Novo Holdings A/S | 7.59% | 99,913 | 471.66K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.62% | 21,382 | 100.94K | Sep 29, 2024 |
| UBS Group AG | 0.39% | 5,099 | 24.07K | Sep 29, 2024 |
| Bank of America Corporation | 0.09% | 1,225 | 5.78K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 490 | 2.31K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 346 | 1.63K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.65% | 8,508 | 40.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 4,541 | 21.44K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.19% | 2,453 | 11.58K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 1,190 | 5.62K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 469 | 2.21K | Oct 30, 2024 |